Impaired glymphatic clearance is an important cause of Alzheimer’s disease

Iyawnna Hazzard , Maryann Batiste , Tianyu Luo , Cyrus Cheung , Forshing Lui

Exploration of Neuroprotective Therapy ›› 2024, Vol. 4 ›› Issue (5) : 401 -410.

PDF (3769KB)
Exploration of Neuroprotective Therapy ›› 2024, Vol. 4 ›› Issue (5) :401 -410. DOI: 10.37349/ent.2024.00091
Mini Review
research-article
Impaired glymphatic clearance is an important cause of Alzheimer’s disease
Author information +
History +
PDF (3769KB)

Abstract

Alzheimer’s disease (AD) is the leading cause of dementia worldwide. The disease is characterized by the abnormal accumulation of amyloid β (Aβ) protein creating neuritic plaques, hyperphosphorylated tau (p-tau) protein forming intracellular tangles, and neuronal degeneration. Pathological changes related to abnormal Aβ and p-tau accumulation may begin more than fifteen years before the clinical diagnosis of AD is made. The glymphatic system is the brain’s waste clearance pathway that prevents the accumulation of these abnormal proteins and macromolecules. Glymphatic clearance is negatively affected by physiological conditions such as sleep deprivation, and pathological conditions such as traumatic brain injury and hemorrhagic strokes. These physiological and pathological conditions are strong risk factors for AD. In conclusion, impaired glymphatic clearance is an important pathogenetic mechanism for AD.

Keywords

Alzheimer’s disease / glymphatic system / amyloid β accumulation / hyperphosphorylated tau protein / neurofibrillary tangles / aquaporin-4

Cite this article

Download citation ▾
Iyawnna Hazzard, Maryann Batiste, Tianyu Luo, Cyrus Cheung, Forshing Lui. Impaired glymphatic clearance is an important cause of Alzheimer’s disease. Exploration of Neuroprotective Therapy, 2024, 4 (5) : 401-410 DOI:10.37349/ent.2024.00091

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Gustavsson A, Norton N, Fast T, Frölich L, Georges J, Holzapfel D, et al. Global estimates on the number of persons across the Alzheimer’s disease continuum. Alzheimers Dement. 2023; 19: 658-70.

[2]

Shokri-Kojori E, Wang G, Wiers CE, Demiral SB, Guo M, Kim SW, et al. β-Amyloid accumulation in the human brain after one night of sleep deprivation. Proc Natl Acad Sci U S A. 2018; 115: 4483-8.

[3]

Jessen NA, Munk ASF, Lundgaard I, Nedergaard M. The Glymphatic System: A Beginner’s Guide. Neurochem Res. 2015; 40: 2583-99.

[4]

Lui F, Zhong N, Wong K, Knowlton S, Alcaide J, Ysit M. A Case of Localized Amyloid Angiopathy Following Aneurysmal Subarachnoid Hemorrhage - Strong Evidence of Dysfunction of the Glymphatic System. Acta Scientific Neurology. 2021; 4: 12-8.

[5]

Atri A. The Alzheimer’s Disease Clinical Spectrum: Diagnosis and Management. Med Clin North Am. 2019; 103: 263-93.

[6]

Alzheimer Disease [Internet]. St. Petersburg: www.ncbi.nlm.nih.gov; c2024 [cited 2024 Jun 17]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499922/

[7]

Silva MVF, Loures CdMG, Alves LCV, Souza LCd, Borges KBG, Carvalho MdG. Alzheimer’s disease: risk factors and potentially protective measures. J Biomed Sci. 2019; 26: 33.

[8]

Holtzman DM, Morris JC, Goate AM. Alzheimer’s disease: the challenge of the second century. Sci Transl Med. 2011; 3: 77sr1.

[9]

Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, et al. Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. Lancet Neurol. 2021; 20: 484-96.

[10]

Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, et al. The Amyloid-β Pathway in Alzheimer’s Disease. Mol Psychiatry. 2021; 26: 5481-503.

[11]

Zhang Y, Thompson R, Zhang H, Xu H. APP processing in Alzheimer’s disease. Mol Brain. 2011; 4: 3.

[12]

Iqbal K, Alonso AdC, Chen S, Chohan MO, El-Akkad E, Gong C, et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta. 2005; 1739: 198-210.

[13]

Bloom GS. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014; 71: 505-8.

[14]

Caselli RJ, Beach TG, Knopman DS, Graff-Radford NR. Alzheimer’s Disease: Scientific Breakthroughs and Translational Challenges. Mayo Clin Proc. 2017; 92: 978-94.

[15]

Smirnov DS, Galasko D, Hiniker A, Edland SD, Salmon DP. Age-at-Onset and APOE-Related Heterogeneity in Pathologically Confirmed Sporadic Alzheimer Disease. Neurology. 2021; 96: e2272-83.

[16]

Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer’s disease. Nat Rev Dis Primers. 2015; 1: 15056.

[17]

Potashman M, Pang M, Tahir M, Shahraz S, Dichter S, Perneczky R, et al. Psychometric properties of the Alzheimer’s Disease Cooperative Study-Activities of Daily Living for Mild Cognitive Impairment (ADCS-MCI-ADL) scale: a post hoc analysis of the ADCS ADC-008 trial. BMC Geriatr. 2023; 23: 124.

[18]

Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann Neurol. 1995; 38: 643-8.

[19]

Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, et al. Rapid Progression from Mild Cognitive Impairment to Alzheimer’s Disease in Subjects with Elevated Levels of Tau in Cerebrospinal Fluid and the APOE ε4/ε4 Genotype. Dement Geriatr Cogn Disord. 2009; 27: 458-64.

[20]

Smirnov DS, Ashton NJ, Blennow K, Zetterberg H, Simrén J, Lantero-Rodriguez J, et al. Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change. Acta Neuropathol. 2022; 143: 487-503.

[21]

Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004; 55: 306-19.

[22]

Armstrong RA. Risk factors for Alzheimer’s disease. Folia Neuropathol. 2019; 57: 87-105.

[23]

Hunsberger HC, Pinky PD, Smith W, Suppiramaniam V, Reed MN. The role of APOE4 in Alzheimer’s disease: strategies for future therapeutic interventions. Neuronal Signal. 2019; 3: NS20180203.

[24]

Hori Y, Hashimoto T, Nomoto H, Hyman BT, Iwatsubo T. Role of Apolipoprotein E in β-Amyloidogenesis: ISOFORM-SPECIFIC EFFECTS ON PROTOFIBRIL TO FIBRIL CONVERSION OF Aβ IN VITRO AND BRAIN Aβ DEPOSITION IN VIVO. J Biol Chem. 2015; 290: 15163-74.

[25]

Li Z, Shue F, Zhao N, Shinohara M, Bu G. APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease. Mol Neurodegener. 2020; 15: 63.

[26]

Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer’s Disease: Advances in Genetics, Pathophysiology, and Therapeutic Approaches. Lancet Neurol. 2021; 20: 68-80.

[27]

Liu C, Zhao N, Fu Y, Wang N, Linares C, Tsai C, et al. ApoE4 Accelerates Early Seeding of Amyloid Pathology. Neuron. 2017; 96: 1024-32.e3.

[28]

Lott IT, Head E. Dementia in Down syndrome: unique insights for Alzheimer disease research. Nat Rev Neurol. 2019; 15: 135-47.

[29]

Graham DI, Gentleman SM, Lynch A, Roberts GW. Distribution of β-amyloid protein in the brain following severe head injury. Neuropathol Appl Neurobiol. 1995; 21: 27-34.

[30]

Roberts GW, Gentleman SM, Lynch A, Graham DI. βA4 amyloid protein deposition in brain after head trauma. Lancet. 1991; 338: 1422-3.

[31]

Johnson VE, Stewart W, Smith DH. Widespread Tau and Amyloid-Beta Pathology Many Years After a Single Traumatic Brain Injury in Humans. Brain Pathol. 2012; 22: 142-9.

[32]

Ramos-Cejudo J, Wisniewski T, Marmar C, Zetterberg H, Blennow K, Leon MJd, et al. Traumatic Brain Injury and Alzheimer’s Disease: The Cerebrovascular Link. EBioMedicine. 2018; 28: 21-30.

[33]

Lucey BP, Hicks TJ, McLeland JS, Toedebusch CD, Boyd J, Elbert DL, et al. Effect of sleep on overnight cerebrospinal fluid amyloid β kinetics. Ann Neurol. 2018; 83: 197-204.

[34]

Lui F, Alcaide J, Knowlton S, Ysit M, Zhong N. Pathogenesis of cerebral amyloid angiopathy caused by chaotic glymphatics-Mini-review. Front Neurosci. 2023; 17: 1180237.

[35]

Bohr T, Hjorth PG, Holst SC, Hrabětová S, Kiviniemi V, Lilius T, et al. The glymphatic system: Current understanding and modeling. iScience. 2022; 25: 104987.

[36]

Municio C, Carrero L, Antequera D, Carro E. Choroid Plexus Aquaporins in CSF Homeostasis and the Glymphatic System: Their Relevance for Alzheimer’s Disease. Int J Mol Sci. 2023; 24: 878.

[37]

Hutton D, Fadelalla MG, Kanodia AK, Hossain-Ibrahim K. Choroid plexus and CSF: an updated review. Br J Neurosurg. 2022; 36: 307-15.

[38]

Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, et al. A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid β. Sci Transl Med. 2012; 4: 147ra111.

[39]

Kaur J, Fahmy LM, Davoodi-Bojd E, Zhang L, Ding G, Hu J, et al. Waste Clearance in the Brain. Front Neuroanat. 2021; 15: 665803.

[40]

Mentis AA, Dardiotis E, Chrousos GP. Apolipoprotein E4 and meningeal lymphatics in Alzheimer disease: a conceptual framework. Mol Psychiatry. 2021; 26: 1075-97.

[41]

Louveau A, Plog BA, Antila S, Alitalo K, Nedergaard M, Kipnis J. Understanding the functions and relationships of the glymphatic system and meningeal lymphatics. J Clin Invest. 2017; 127: 3210-9.

[42]

Albargothy NJ, Johnston DA, MacGregor-Sharp M, Weller RO, Verma A, Hawkes CA, et al. Convective influx/glymphatic system: tracers injected into the CSF enter and leave the brain along separate periarterial basement membrane pathways. Acta Neuropathol. 2018; 136: 139-52.

[43]

Natale G, Limanaqi F, Busceti CL, Mastroiacovo F, Nicoletti F, Puglisi-Allegra S, et al. Glymphatic System as a Gateway to Connect Neurodegeneration From Periphery to CNS. Front Neurosci. 2021; 15: 639140.

[44]

Sakka L, Coll G, Chazal J. Anatomy and physiology of cerebrospinal fluid. Eur Ann Otorhinolaryngol Head Neck Dis. 2011; 128: 309-16.

[45]

Kress BT, Iliff JJ, Xia M, Wang M, Wei HS, Zeppenfeld D, et al. Impairment of paravascular clearance pathways in the aging brain. Ann Neurol. 2014; 76: 845-61.

[46]

Achariyar TM, Li B, Peng W, Verghese PB, Shi Y, McConnell E, et al. Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation. Mol Neurodegener. 2016; 11: 74.

[47]

Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med. 2011; 3: 89ra57.

[48]

Gaberel T, Gakuba C, Goulay R, Lizarrondo SMD, Hanouz J, Emery E, et al. Impaired glymphatic perfusion after strokes revealed by contrast-enhanced MRI: a new target for fibrinolysis? Stroke. 2014; 45: 3092-6.

[49]

Quintin S, Barpujari A, Mehkri Y, Hernandez J, Lucke-Wold B. The glymphatic system and subarachnoid hemorrhage: disruption and recovery. Explor Neuroprot Ther. 2022; 118-30.

PDF (3769KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉